GDRX logo

GoodRx Holdings, Inc. Stock Price

NasdaqGS:GDRX Community·US$1.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 31 Fair Values set on narratives written by author

GDRX Share Price Performance

US$3.72
0.18 (5.08%)
US$2.50
Fair Value
US$3.72
0.18 (5.08%)
48.8% overvalued intrinsic discount
US$2.50
Fair Value
Price US$3.72
AnalystLowTarget US$2.50
AnalystConsensusTarget US$3.18
AnalystHighTarget US$4.00

GDRX Community Narratives

·
Fair Value US$2.5 48.8% overvalued intrinsic discount

Government Pricing Reforms And Tech Rivalries Will Reduce Future Prospects

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$3.18 17.0% overvalued intrinsic discount

Digital Health And Telemedicine Expansion Will Deepen Market Opportunity

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
·
Fair Value US$4 7.0% undervalued intrinsic discount

Digital Transformation And Aging Trends Will Expand Affordable Prescription Access

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

GDRX logo

GDRX: Rising Wegovy Reliance Will Pressure Future Prescription Margin Sustainability

Fair Value: US$2.5 48.8% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
GDRX logo

GDRX: Membership Expansion And Higher Margins Will Reset Prescription Economics

Fair Value: US$4 7.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
GDRX logo

GDRX: Pharma Direct Shift And New Offerings Will Support Future Upside

Fair Value: US$3.18 17.0% overvalued intrinsic discount
13 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with moderate growth potential.

2 Risks
2 Rewards

GoodRx Holdings, Inc. Key Details

US$785.2m

Revenue

US$72.0m

Cost of Revenue

US$713.2m

Gross Profit

US$696.9m

Other Expenses

US$16.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.048
90.83%
2.07%
75.1%
View Full Analysis

About GDRX

Founded
2011
Employees
697
CEO
Wendy Barnes
WebsiteView website
www.goodrx.com

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Recent GDRX News & Updates

Seeking Alpha Aug 12

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

Summary GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating. Despite operational progress, risk-reward remains balanced at current valuations, justifying a cautious stance. Read the full article on Seeking Alpha
Narrative Update Aug 07

GDRX: Rising Wegovy Reliance Will Pressure Future Prescription Margin Sustainability

Analysts have lifted their price target on GoodRx Holdings to $5 from $3.50, reflecting updated views on fair value, growth assumptions and profit potential, supported by recent research highlighting factors such as Wegovy prescription activity and revised earnings estimates. Analyst Commentary on GoodRx Holdings Recent research on GoodRx highlights a mixed tone.

Recent updates

No updates